10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
62.65
-0.57 (-0.90%)
At close: Sep 4, 2026, 4:00 PM EDT
62.39
-0.26 (-0.42%)
After-hours: Sep 4, 2026, 7:30 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, 10x Genomics stock has a consensus rating of "Buy" and an average price target of $51. The average 1-year stock price forecast is 18.60% lower than the current stock price, while the lowest is $40 (-36.15%) and the highest is $70 (+11.73%).
Price Target: $51 (-18.60%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 10 | 10 | 10 | 10 | 10 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Initiates $70 | Hold | Initiates | $70 | +11.73% | Sep 1, 2026 |
Unknown Analyst Stephens No rating | Stephens | Buy Reiterates $65 | Buy | Reiterates | $65 | +3.75% | Aug 12, 2026 |
| J.P. Morgan | J.P. Morgan | Hold Maintains $38 → $50 | Hold | Maintains | $38 → $50 | -20.19% | Aug 11, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $50 | Buy | Maintains | $50 | -20.19% | Aug 11, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $50 → $60 | Buy | Reiterates | $50 → $60 | -4.23% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
620.39M
from 642.82M
Decreased by -3.49%
Revenue Next Year
679.96M
from 620.39M
Increased by 9.60%
EPS This Year
0.11
from 0.12
Decreased by -14.70%
EPS Next Year
0.20
from 0.11
Increased by 93.65%
EPS and Forward PE are based on non-GAAP adjusted numbers.